A new trading day began on Monday, with Cardiff Oncology Inc (NASDAQ: CRDF) stock price up 10.90% from the previous day of trading, before settling in for the closing price of $2.11. CRDF’s price has ranged from $1.90 to $5.64 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 19.36%. Meanwhile, its annual earnings per share averaged 18.98%. With a float of $61.28 million, this company’s outstanding shares have now reached $67.09 million.
Cardiff Oncology Inc (CRDF) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cardiff Oncology Inc is 9.02%, while institutional ownership is 31.32%. The most recent insider transaction that took place on Jul 30 ’25, was worth 673,750. In this transaction Director of this company bought 275,000 shares at a rate of $2.45, taking the stock ownership to the 1,330,676 shares. Before that another transaction happened on Jul 30 ’25, when Company’s Director bought 15,000 for $2.45, making the entire transaction worth $36,750. This insider now owns 1,345,676 shares in total.
Cardiff Oncology Inc (CRDF) Latest Financial update
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.21 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 18.98% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.04% during the next five years compared to 19.36% growth over the previous five years of trading.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
Here are Cardiff Oncology Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 315.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.79, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.75 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
The latest stats from [Cardiff Oncology Inc, CRDF] show that its last 5-days average volume of 0.91 million was inferior to 1.25 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 57.09%.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 16.57%, which indicates a significant decrease from 93.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.13 in the past 14 days, which was lower than the 0.15 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.20, while its 200-day Moving Average is $2.86. Now, the first resistance to watch is $2.44. This is followed by the second major resistance level at $2.53. The third major resistance level sits at $2.70. If the price goes on to break the first support level at $2.18, it is likely to go to the next support level at $2.01. The third support level lies at $1.92 if the price breaches the second support level.
Cardiff Oncology Inc (NASDAQ: CRDF) Key Stats
With a market capitalization of 157.62 million, the company has a total of 67,361K Shares Outstanding. Currently, annual sales are 680 K while annual income is -45,430 K. The company’s previous quarter sales were 120 K while its latest quarter income was -11,260 K.
